High speed detection of circulating tumor cells

Hsieh, H. C.; Marrinucci, Dena; Bethel, Kelly; Curry, Douglas N.; Humphrey, Mark; Krivacic, Robert T.; Kroener, Joan F.; Kroener, Lindsay; Ladányi, András; Lazarus, Nicole H.; Kühn, Peter; Bruce, Richard H.; Nieva, Jorgé

doi:10.1016/j.bios.2005.12.024

Cited by 159 publications

(104 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detection of CTCs in blood is a noninvasive method of sampling and studying tumour cells compared to classic biopsy. Most CTCs enrichment methods are based on the use of EpCAM-specific antibodies and subsequent detection using anti-cytokeratin [13,14,29,30]. EpCAM is a surface marker found only on carcinoma cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines

Sterzyńska

Kempisty²,

Zawierucha³

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:The epithelial cell adhesion molecule (EpCAM) is a membrane glycoprotein that is expressed in most normal human epithelia and overexpressed in most carcinomas. This molecule is responsible for cell-to-cell adhesion and additionally participates in signalling, cell migration, proliferation and differentiation. Therefore, EpCAM has been the target of immunotherapy in clinical trials of several solid tumours. It has been found to play an important role in the detection and isolation of circulating tumour cells (CTCs). The aim of this study was to investigate and compare the specificity and selectivity of different anti-EpCAM antibodies in order to assess their usefulness for CTCs binding. All experiments were performed in six different types of breast cancer cell lines (MCF-7, SkBr-3, T47D, CAMA-1, MDAMB-231, and BT-20) and using three different anti-EpCAM antibodies (EBA-1, AUA-1, and 9C4). Immunofluorescence and Real-Time PCR techniques were applied to analyse the protein and gene expression levels. The experiments revealed that the investigated antibodies differed significantly regarding the specificity of EpCAM antigen binding. The most significant role in targeting CTCs was played by the EBA-1 and 9C4 anti-EpCAM antibodies. They revealed the strongest immunofluorescent signal among other applied antibodies and/or were specific for all examined breast cancer cell lines. The strength and specificity of reaction was dependent not only on the type of antibody, but also on the type of breast cancer cell line. We noted that the diverse sensitivities of reactions depended on the type of applied antibody. We therefore recommend the simultaneous application of different anti-EpCAM antibodies. An appropriate choice of anti-EpCAM antibodies and an evaluation of EpCAM expression in breast cancer appear to be crucial, especially as this antigen is being proposed as a marker for the detection of circulating tumour cells.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In most studies, CTCs are defined as being positive for EpCAM and cytokeratins 8, 18 and 19, and negative for CD45. Therefore, some CTC enrichment methods are based on the use of anti-EpCAM antibodies and subsequent detection with anti-cytokeratin antibodies [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines

Sterzyńska

Kempisty²,

Zawierucha³

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…The ADM system was further refined by the development of a fiber-optic array scanning technology (FAST) which allowed for scan rates 500 times faster than the conventional ADM (18 (20). The premise of the CellSearch method ( Figure 1) hence capitalizes on this EpCAM expression: epithelial cells from samples of peripheral whole blood are immunomagnetically enriched by incubation with EpCAM specific immunomagnetic ferrofluid, then stained with CD45, DAPI, and cytokeratins 8, 18, and 19.…”

Section: Historymentioning

confidence: 99%

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Nieva

2017

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

An understanding of cancer evolution in lung cancer with its associated resistance to therapy can only be achieved with repeated sampling and analysis of the cancer. Given the high risks and costs associated with repeat physical biopsy, alternative technologies must be applied. Several modalities exist for analysis and re-analysis of cancer biology. Among them are the CellSearch platform, the CTC chip, and the highdefinition CTC platform. While the former is primarily able to provide prognosticating information in the form of CTC enumeration, the latter two have the advantage of serving as a platform to study tumor biology. Techniques for analysis of single cell genomics, as well as protein expression on a single cell basis provide scientists with the capacity to understand cancer cell populations as a collection of individual cells, rather than as an average of all cells. A multimodal combination of circulating tumor DNAs (ctDNAs), CTCs, proteomics, and CTC-derived xenografts (CDXs) to create computational models useful in diagnosis, prognostication, and predictiveness to treatment is likely the future of tailoring individualized cancer care.

show abstract

“…In addition to the biophysical property of density, the tendency of CTCs to form clusters rather than individual cells was reported 32, 33, 34. With the development of microscopy and fluorescent staining technologies, more insight into the biophysical properties of CTCs including size and deformability were provided recently 35, 36. Several studies in breast cancer and lung adenocarcinoma noted that the size of CTCs was typically larger than blood cells, which has been an important criteria generally used for current CTCs capture and isolation 37, 38.…”

Section: Biophysical and Biochemical Properties Of Ctcsmentioning

confidence: 99%

Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells

Chandran

Lim

et al. 2015

Advanced Science

View full text Add to dashboard Cite

Originating from primary tumors and penetrating into blood circulation, circulating tumor cells (CTCs) play a vital role in understanding the biology of metastasis and have great potential for early cancer diagnosis, prognosis and personalized therapy. By exploiting the specific biophysical and biochemical properties of CTCs, various material interfaces have been developed for the capture and detection of CTCs from blood. However, due to the extremely low number of CTCs in peripheral blood, there exists a need to improve the efficiency and specificity of the CTC capture and detection. In this regard, a critical review of the numerous reports of advanced platforms for highly efficient and selective capture of CTCs, which have been spurred by recent advances in nanotechnology and microfabrication, is essential. This review gives an overview of unique biophysical and biochemical properties of CTCs, followed by a summary of the key material interfaces recently developed for improved CTC capture and detection, with focus on the use of microfluidics, nanostructured substrates, and miniaturized nuclear magnetic resonance‐based systems. Challenges and future perspectives in the design of material interfaces for capture and detection of CTCs in clinical applications are also discussed.

show abstract

High speed detection of circulating tumor cells

Cited by 159 publications

References 12 publications

Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines

Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Rational Design of Materials Interface for Efficient Capture of Circulating Tumor Cells

Contact Info

Product

Resources

About